CD4 and tuberculosis: Two human adenovirus-based recombinant vaccines against TB, AdAg85A (also known as AdHu5Ag85A) and AERAS-402 (also known as Crucell Ad35), in addition to ChAdOx1.85A, based on a chimpanzee adenovirus vector, are capable of inducing a strong CD8+ T-cell immune response in addition to high levels of Th1-type CD4+ T-cell immune response.